BioDelivery Sciences International (BDSI) : Traders are bullish on BioDelivery Sciences International (BDSI) as it has outperformed the S&P 500 by a wide margin of 6.53% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 14.11%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 14.17% in the last 1 week, and is up 7.63% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 15.64% and the 50-Day Moving Average is 14.79%. BioDelivery Sciences International (NASDAQ:BDSI): stock turned positive on Friday. Though the stock opened at $2.75, the bulls momentum made the stock top out at $2.89 level for the day. The stock recorded a low of $2.645 and closed the trading day at $2.82, in the green by 6.42%. The total traded volume for the day was 1,203,163. The stock had closed at $2.65 in the previous days trading.
The company Insiders own 9% of BioDelivery Sciences International shares according to the proxy statements. Institutional Investors own 71.88% of BioDelivery Sciences International shares. During last six month period, the net percent change held by insiders has seen a change of 14.41%. Also, Cantor Fitzgerald downgrades its rating on BioDelivery Sciences International (NASDAQ:BDSI). The global brokerage major lowers the current price target from $9 per share to $5 per share. Analysts at the Cantor Fitzgerald have a current rating of Hold on the shares. The shares were previously rated Buy. The rating by the firm was issued on May 11, 2016.
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Companys products and certain of its product candidates utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Companys United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved product BUNAVAIL (buprenorphine and naloxone buccal film) and its product candidate, BELBUCA utilize its BEMA technology.